Biotech · Private company
NewAmsterdam Pharma
Track this companyFree. Adds NewAmsterdam Pharma to your Dealase workspace and tells you when its record changes.
Clinical trials177 recruiting or active
Pipeline programs18From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline18
- Combination TherapyPhase 3 · DyslipidemiasClinicalTrials.gov · fetched Nov 12, 2026
- Monotherapy ezetimibePhase 3 · DyslipidemiasClinicalTrials.gov · fetched Nov 12, 2026
- Monotherapy obicetrapibPhase 3 · DyslipidemiasClinicalTrials.gov · fetched Nov 12, 2026
- ObicetrapibPhase 3 · Atherosclerotic Cardiovascular DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- ObicetrapibPhase 3 · DyslipidemiasClinicalTrials.gov · fetched Nov 12, 2026
- Obicetrapib 10 mgPhase 3 · LipidemiaClinicalTrials.gov · fetched Nov 12, 2026
- obicetrapib 10 mg + ezetimibe 10 mg FDC dailyPhase 3 · LipidemiaClinicalTrials.gov · fetched Nov 12, 2026
- Ezetimibe 10mgPhase 2 · DyslipidemiasClinicalTrials.gov · fetched Nov 12, 2026
- Obicetrapib 10 mgPhase 2 · Preclinical Alzheimer's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeksPhase 2 · DyslipidemiasClinicalTrials.gov · fetched Nov 12, 2026
- Obicetrapib 10mgPhase 2 · Antioxidant AbsorptionClinicalTrials.gov · fetched Nov 12, 2026
- Obicetrapib 5mgPhase 2 · DyslipidemiasClinicalTrials.gov · fetched Nov 12, 2026
- Drospirenone / Ethinyl Estradiol (COC)Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- Fixed-Dose Combination (FDC) TabletPhase 1 · Healthy Volunteer StudyClinicalTrials.gov · fetched Nov 12, 2026
- ObicetrapibPhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- ObicetrapibPhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
- ObicetrapibPhase 1 · Lipid MetabolismClinicalTrials.gov · fetched Nov 12, 2026
- Obicetrapib + Drospirenone / Ethinyl Estradiol (COC)Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials17
- Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's DiseasePHASE2 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07794670 · fetched Nov 12, 2026
- A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic SyndromePHASE3 · ACTIVE_NOT_RECRUITING · started Dec 11, 2025ClinicalTrials.gov NCT07219602 · fetched Nov 12, 2026
- Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy VolunteersPHASE2 · RECRUITING · started Sep 9, 2025ClinicalTrials.gov NCT06982508 · fetched Nov 12, 2026
- Impact of the Corrie Lipids Digital Health Program on Lipid OptimizationNA · RECRUITING · started Jun 20, 2025ClinicalTrials.gov NCT07478887 · fetched Nov 12, 2026
- Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) LevelsPHASE2 · RECRUITING · started Dec 2, 2024ClinicalTrials.gov NCT06496243 · fetched Nov 12, 2026
- A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary PlaquePHASE3 · ACTIVE_NOT_RECRUITING · started May 16, 2024ClinicalTrials.gov NCT06305559 · fetched Nov 12, 2026
- Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying TherapiesPHASE3 · COMPLETED · started Mar 1, 2024ClinicalTrials.gov NCT06005597 · fetched Nov 12, 2026
- Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without ObicetrapibPHASE1 · COMPLETED · started Feb 5, 2024ClinicalTrials.gov NCT06250205 · fetched Nov 12, 2026
- Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and EzetimibePHASE1 · COMPLETED · started Jan 20, 2024ClinicalTrials.gov NCT06050291 · fetched Nov 12, 2026
- Investigating the Effect of Obicetrapib on Lipoprotein MetabolismPHASE1 · UNKNOWN · started Dec 1, 2023ClinicalTrials.gov NCT05972278 · fetched Nov 12, 2026
- PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic FunctionPHASE1 · COMPLETED · started Nov 30, 2023ClinicalTrials.gov NCT06048302 · fetched Nov 12, 2026
- Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.PHASE3 · COMPLETED · started Jul 25, 2022ClinicalTrials.gov NCT05425745 · fetched Nov 12, 2026
- Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS TherapyPHASE2 · COMPLETED · started Mar 9, 2022ClinicalTrials.gov NCT05266586 · fetched Nov 12, 2026
- Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseasePHASE3 · ACTIVE_NOT_RECRUITING · started Feb 7, 2022ClinicalTrials.gov NCT05202509 · fetched Nov 12, 2026
- Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesPHASE3 · COMPLETED · started Dec 15, 2021ClinicalTrials.gov NCT05142722 · fetched Nov 12, 2026
- Randomized Study of Obicetrapib in Combination With EzetimibePHASE2 · COMPLETED · started Feb 23, 2021ClinicalTrials.gov NCT04770389 · fetched Nov 12, 2026
- Randomized Study of Obicetrapib as an Adjunct to Statin TherapyPHASE2 · COMPLETED · started Feb 18, 2021ClinicalTrials.gov NCT04753606 · fetched Nov 12, 2026